Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF InhibitorAccesswire • 08/24/21
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/04/21
Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateAccesswire • 08/04/21
Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021Accesswire • 07/28/21
Pieris Stock Moves Higher On €14.2M Grant For PRS-220 In Post-COVID Pulmonary FibrosisBenzinga • 06/25/21
Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary FibrosisAccesswire • 06/25/21
Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric CancerAccesswire • 06/24/21
Are Options Traders Betting on a Big Move in Pieris (PIRS) Stock?Zacks Investment Research • 05/26/21
Pieris stock rockets on record volume after Genentech collaboration valued at up to $1.4 billionMarket Watch • 05/25/21